Publicacións en colaboración con investigadores/as de Hospital Universitario Central de Asturias (9)

2023

  1. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 8, pp. 594-602

  2. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  3. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162

2019

  1. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice-Vie-KinD study

    PLoS ONE, Vol. 14, Núm. 9

2017

  1. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  2. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148

  3. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection

    Clinical Gastroenterology and Hepatology, Vol. 15, Núm. 6, pp. 945-949.e1

2015

  1. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

    World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174

  2. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

    Journal of Viral Hepatitis, Vol. 22, Núm. 5, pp. 469-480